2024
Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy
Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.Peer-Reviewed Original ResearchProstate Health IndexMRI-ultrasound fusion targeted biopsyClinically significant prostate cancerFusion targeted biopsyPI-RADS 1Gleason grade groupMagnetic resonance imagingPhi densityPI-RADSProstate specific-antigenProstate biopsyImproved detection of clinically significant prostate cancerDetection of clinically significant prostate cancerPHI testingProstate health index densityElevated prostate-specific antigenMRI-ultrasound fusionProstate Imaging ReportingSignificant prostate cancerProstate-specific antigenSelection of patientsDetection of PCaReceiver operating characteristic curveCombination of magnetic resonance imagingMultivariate logistic regression
2023
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.
Moses K, Sprenkle P, Bahler C, Box G, Carlsson S, Catalona W, Dahl D, Dall'Era M, Davis J, Drake B, Epstein J, Etzioni R, Farrington T, Garraway I, Jarrard D, Kauffman E, Kaye D, Kibel A, LaGrange C, Maroni P, Ponsky L, Reys B, Salami S, Sanchez A, Seibert T, Shaneyfelt T, Smaldone M, Sonn G, Tyson M, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi R, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 236-246. PMID: 36898362, DOI: 10.6004/jnccn.2023.0014.Peer-Reviewed Original ResearchConceptsProstate cancer early detectionNCCN guidelinesCancer early detectionEarly detectionNCCN Guidelines InsightsNegative biopsy resultsEarly Detection ProgramSignificant prostate cancerIndolent diseaseBiopsy resultsAppropriate counselingProstate cancerMultiparametric MRIDetection programRecent updatesGuidelinesTesting protocol
2022
Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions
Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana‐Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais‐Bahrami S. Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions. Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.Peer-Reviewed Original ResearchConceptsPI-RADS 3 lesionsHigher prostate specific antigen densitySignificant prostate cancerProstate-specific antigen densityPrior negative biopsyNegative biopsyMagnetic resonance imagingProstate cancerPSA densityValidation cohortEquivocal lesionsAntigen densityResonance imagingMultivariable logistic regression modelData System (PI-RADS) 3 lesionsMultiparametric magnetic resonance imagingElevated PSA densityMulti-institutional analysisDecision curve analysisProstate Imaging ReportingDetection of csPCaLogistic regression modelsMultivariable analysisSubsequent biopsyTraining cohortClinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer
Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.Peer-Reviewed Original ResearchConceptsActive surveillanceIndex lesionProstate biopsyProstate cancerMultiparametric magnetic resonance imagingData System version 2Low-risk CaPSurveillance prostate biopsyGleason grade groupMultivariate logistic regressionSignificant prostate cancerProstate Imaging ReportingReceiver operator characteristic curvePI-RADS 2Low-suspicion lesionsOperator characteristic curveMagnetic resonance imagingHigher PSADOnly significant variablePrimary outcomeMultivariable analysisSystematic biopsyRetrospective analysisBiopsy approachImaging ReportingPD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS
Fang A, Shumaker L, Martin K, Onah O, Jackson J, Khajir G, Fan R, Soodana-Prakash N, Patel H, Vourganti S, Filson C, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2022, 207: e959. DOI: 10.1097/ju.0000000000002637.01.Peer-Reviewed Original Research
2021
MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS
Fang A, Shumaker L, Khajir G, Fan R, Soodana-Prakash N, Patel H, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2021, 206: e78-e78. DOI: 10.1097/ju.0000000000001972.05.Peer-Reviewed Original Research
2018
MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY?
Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Journal Of Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.Peer-Reviewed Original ResearchClinically Significant Prostate CancerSignificant prostate cancerMRI-ultrasound fusion biopsyFusion biopsyProstate cancerRole of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions.
Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyProstate lesionsSignificant cancerProstate cancerSignificant cancer detection rateMRI-US fusion biopsyHigher PIRADS scoresHigh Gleason scoreSignificant prostate cancerMRI-ultrasound fusion biopsyProstate Imaging ReportingClinical suspicionGleason scorePIRADS scoreBiopsy histologyTemplate biopsyDetection rateLesion volumePathology gradeBiopsy coresMultiparametric MRILesion basisBiopsyImaging ReportingHow many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?
Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyMulti-parametric MRILesion basisMRI-US fusion biopsyHistory of PCaHigh-grade cancerSignificant prostate cancerMRI-ultrasound fusion biopsyMpMRI studiesClinical suspicionPrimary outcomeSignificant PCaLesion biopsyDetection rateProstate cancerBiopsy coresBiopsyRegion of interestLesion targetingGenitourinary radiologistsCancerLesionsPatientsOne-quarterIs PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?
Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.Peer-Reviewed Original ResearchSmaller prostate volumeMulti-parametric MRISignificant prostate cancerProstate volumeProstate cancerROI ratioPSA densityGrade groupPrediction of csPCaRisk of csPCaData System (BI-RADS) category 3Prostate Imaging ReportingMpMRI findingsBiopsy databasePrior diagnosisTargeted biopsiesFusion biopsyPositive coresCsPCaUnnecessary biopsiesBiopsyMultivariate analysisPatientsImaging ReportingLesions
2016
MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.Peer-Reviewed Original ResearchPrior negative biopsyCS cancerGleason scoreNegative MRIProstate cancerNegative biopsyCS prostate cancerMRI suspicion scoreMRI-US fusionPre-biopsy mpMRIFusion prostate biopsyMRI-ultrasound fusionSignificant prostate cancerCancer detection rateBiopsy of lesionsMaximum Gleason scoreMulti-parametric MRIElevated PSAPrevious biopsyRepeat biopsyMapping biopsyBiopsy resultsProstate biopsyFusion biopsyStandard biopsy
2015
Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy.
Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.Peer-Reviewed Original ResearchCancer detection rateOverall cancer detection rateSignificant prostate cancerProstate cancerSystematic biopsyProstate biopsyFusion biopsyCommon solid organ malignancyEndorectal coilCores TRUS biopsyPrior negative biopsySolid organ malignanciesFusion prostate biopsyCochran-Armitage trend testCause of cancerMagnetic resonance imagingReal-time ultrasoundArmitage trend testAbnormal DRELesion stratificationElevated PSAOrgan malignanciesLesion gradingNegative biopsyTRUS biopsy